At the current 57th WHO Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances meeting in Geneva, Hospira has echoed Mylan and GPhA's sentiment that biosimilars receive thesame INN as the original biologic. Hospira Senior VP & Chief Scientific Officer, Dr. Sumant Ramachandra, said Europe has been doing this for 6 years without a problem in tracking biosimilars on the market without any confusion with the originator drug.
But, members of BIO and PhRMA continue to call for unique names to be used with the biological products. They say this is necessary for pharmacovigilance and patient safety. However, what they really want to do is make interchangeability more difficult in the US and therefore slow down market penetration with concommitant loss of revenue of original biologics. See BioPharma.Reporter.
Posed by Bruce Lehr Oct 23rd 2013.